To our knowledge, this is the first study that analyzed 5-mC alterations in cfDNA of ALK-rearranged NSCLC and comprehensively monitored their targeted TKI therapy using 5-mC biomarkers. This evidence concerns the gene ALK and non-small cell lung carcinoma.